Practical pharmacotherapy for acute schizophrenia patients

Abstract

Well-organized clinical guidelines of pharmacotherapy for schizophrenia are not necessarily applicable to emergency and acute-phase situations. Thus, practical pharmacotherapy for acute schizophrenia patients should be based on data from real clinical practice and be independent of pharmaceutical companies. This study investigated the current guidelines being used to determine the initially preferred antipsychotics, durations required before an antipsychotic is viewed as being ineffective, and the strategies utilized for early non-responders that include switching, high dose, and augmentation. In patients who develop side-effects to the preferred antipsychotic drug, continued use may depend on the specific characteristics of the side-effects. For acute-phase patients, antipsychotics with high efficacy and effectiveness may be chosen based on meta-analysis findings for not only double-blinded but also raterblinded randomized controlled trials. Many previous studies have reported being able to make an early prediction at 2 weeks regarding the later response. These predictions were supported by the findings of a recent meta-analysis of 34 studies that examined 9975 participants. In early non-responders to the initial antipsychotic, the effectiveness of the switching strategy appears to depend on the initial antipsychotic administered and the antipsychotic the patient is subsequently switched to. Furthermore, the effectiveness of the strategy between switching and augmentation might also depend on the initial antipsychotic administered. The current findings might serve as the basis for the use of dosing above the licensed range versus continuing the use of conventional dosing in non-responders, provided there is close monitoring of the side-effects. Further research is required before any modifications of routine practices are undertaken regarding the direction of new potential treatments.

Early detection and integrated care for adolescents and young adults with psychotic disorders: the ACCESS III study

“…Furthermore, we cannot rule out that the external assessments themselves may have further increased service engagement. However, this “real‐life” approach was chosen to increase the likelihood of an unbiased inclusion of severely ill psychosis patients that would probably have denied study participation when included in a (randomized) controlled trial .…”

Fast In Vitro Release and In Vivo Absorption of an Anti-Schizophrenic Drug Paliperidone from Its Soluplus®/TPGS Mixed Micelles

“…The prevalence rate of this disease can reach 6.55‰ in China [ 2 ]. Acute schizophrenia is a kind of schizophrenia with acute onset and short course, which is mainly characterized by positive symptoms, such as delusions, hallucinations, behavior disorders and agitation [ 3 ]. Patients with acute schizophrenia are often destructive and dangerous to themselves and others [ 4 ].…”